Drug Eluting Stents Market Size, Share, Industry, Forecast and outlook (2024-2031)

Drug Eluting Stents Market is segmented By Coating (Polymer-based coating stents (Non-biodegradable polymer, Biodegradable polymer), Polymer-free coating stents), By Application (Coronary Artery Diseases, Peripheral Artery Disease), By End-user (Hospitals, Ambulatory Surgical Centers, Cardiac Centers), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Drug Eluting Stents Market Size

The Global Drug Eluting Stents Market reached USD 6.3 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 10.2 billion by 2031. The global drug eluting stents market is expected to exhibit a CAGR of 6.4% during the forecast period (2024-2031). The global market for drug-eluting stents (DES) has grown significantly in recent years. In interventional cardiology treatments, drug-eluting stents are frequently utilized to treat coronary artery disease. These stents are designed to gradually release medications, lowering the risk of restenosis and increasing patient outcomes. 

Some of the latest trends in the globally drug-eluting stents market include the use of biodegradable stents, next-generation drug-eluting stents, expansion into peripheral arterial diseases, and a personalized medicine approach. The global drug eluting stents market growth is driven by factors such as technological advancements, an increasingly aging population, a rising prevalence of cardiovascular disease, increasing drug approvals, and rising patient healthcare expenditure.

Drug Eluting Stents Market Summary

For more Insights - Request Free Sample

Drug Eluting Stents Market Dynamics

The Rising Prevalence of Cardiovascular Disease will Drive the Global Drug Eluting Stents Market Growth

Cardiovascular diseases, such as coronary artery disease and atherosclerosis, are growing more common around the globe. These diseases can cause artery blockages, reducing blood flow and potentially triggering heart attacks or strokes. The rising prevalence of cardiovascular illnesses is a significant driver of the drug-eluting stents industry.

For instance, according to a 2023 report by the Centers for Disease Control and Prevention (CDC), heart disease accounted for approximately 695,000 deaths in the United States in 2021, accounting for one in every five deaths. Coronary heart disease was the most common type of heart disease, killing 375,476 persons in the same year. 

In addition, approximately 805,000 people in the United States have a heart attack each year. Heart disease imposes a significant economic burden, costing the United States around USD 239.9 billion per year from 2018 to 2019, including healthcare costs, pharmaceuticals, and lost productivity due to early death. Hence, owing to the above factors, the global drug eluting stents market is expected to drive over the forecast period.

The Growing Technological Advancements will Drive the Global Drug Eluting Stents Market Growth

Continuous improvements in drug-eluting stent technology contribute significantly to market growth. These developments include a wide range of stent technology topics, including design, medication formulation, and coating techniques. Continuous development in these areas has resulted in substantial benefits for both patients and healthcare providers, thereby driving the global drug eluting stents market over the forecast period.

For instance, the National Library Medicine article published in Current Atherosclerosis Reports journal in 2022 states that the drug eluting stent (DES) design has developed over time in an effort to enhance patient outcomes. Early DES were manufactured with thick struts, which could promote inflammation and arterial constriction. 

Later, thinner struts were used in DES, lowering the risk of inflammation and constriction. DES has recently been produced with bioresorbable polymers that are absorbed by the body over time. Bioresorbable polymers may be able to lower the risk of late stent thrombosis, a major consequence of DES. The use of DES has been found to improve patient outcomes.

The Risks Associated with Drug-Eluting Stents Will Hamper the Growth of The Global Drug Eluting Stents Market

Angioplasty is a less intrusive alternative to bypass surgery for treating clogged arteries, but it is not without risk. When drug-eluting stents are used in conjunction with angioplasty, re-narrowing of the artery is a worry, as there is a small possibility that the previously treated artery will become clogged again. 

This danger is heightened when bare-metal stents are used. Furthermore, there are rare but substantial dangers linked with angioplasty, such as heart attacks, coronary artery damage, kidney issues, and strokes. Moreover, balloon angioplasty, percutaneous coronary intervention (PCI), and coronary artery bypass grafting (CABG) are some of the alternatives to drug eluting stents that will hamper the market growth

Drug Eluting Stents Market Segmentation

The global drug eluting stents market is segmented based on coating, application, end user, and region.

The Polymer-based Coating Segment is Expected to Hold a Dominant Position in the Global Drug Eluting Stents Market Over the Forecast Period

The polymer-based coating segment is projected to dominate the global drug eluting stents market accounting market share of about 52.7%, owing to the improved biocompatibility, controlled drug release, advancements in polymer technology, reduced risk of adverse reactions and promoting faster endothelial healing. 

Polymer-based coatings have been widely used in drug-eluting stents to enable controlled drug release and improve stent therapeutic efficacy. These coatings provide a solid platform for drug incorporation with controlled-release kinetics, ensuring effective drug delivery to the target site. Furthermore, polymer coatings improve biocompatibility, lowering the probability of adverse responses and facilitating quicker endothelium repair.

The discovery of a new stent coating that offers controlled sirolimus release from a bioactive polymer is one of the most recent advances in drug-eluting stents. To help avoid re-narrowing of the coronary artery, the Svelte stent system slowly delivers sirolimus from the stent surface into the coronary artery wall. Sirolimus is a medication that suppresses the proliferation of vascular smooth muscle cells and is utilized in drug-eluting stents. 

The stents are covered in a multiple-layer system with biodegradable polymers as a carrier, allowing for regulated sirolimus drug delivery for up to four weeks. Sirolimus was recognized as a better medicine for stent treatment due to its ability to suppress vascular smooth muscle cell proliferation. Therefore, owing to the above factors, the global drug eluting stents market is expected to grow over the forecast period.

Source: DataM Intelligence Analysis (2023)

Drug Eluting Stents Market Geographical Share

North America Holds a Dominant Position in the Global Drug Eluting Stents Market

North America is estimated to hold around 39.6% of the total market share throughout the forecast period. The increasing prevalence of cardiovascular disease, the rising geriatric population, clinical research and trials, high healthcare expenditure, advanced healthcare infrastructure and key regional players are some of the key factors expected to drive the global drug-eluting stents market growth in North America region over the forecast period.

For instance, according to World Health Organization (WHO) 2022 report, by 2030, about one out of every six people on the planet will be 60 or older. Within this time span, the share of the world population aged 60 and up is expected to increase from 1 billion in 2020 to 1.4 billion. In 2050, the number of persons aged 60 and up will more than treble, approaching 2.1 billion. 

Source: DataM Intelligence Analysis (2023)

Drug Eluting Stents Market Key Players

The major global players in the market include Boston Scientific Corp., Abbott Laboratories, Medtronic Plc, Biotronik Inc., Johnson & Johnson, MicroPort Scientific Corporation, Cook Medical Inc., Stentys S.A., Biosensors International Group, and Terumo Corp., among others.

COVID-19 Impact on Drug Eluting Stents Market

The global drug eluting stent (DES) market has been significantly impacted by the COVID-19 pandemic. As hospitals focused on treating COVID-19 patients, the number of elective treatments, including DES implantations, decreased. Furthermore, because to travel restrictions and social distancing efforts, the epidemic has reduced patient access to healthcare. This has made it more difficult for patients to receive necessary therapy, such as DES implantations.

The COVID-19 epidemic has also raised the cost of DES implantations. This is due to a variety of causes, including greater PPE costs and the necessity for more complex procedures due to the increased risk of infection. The rising expense of DES implantations has made this treatment increasingly difficult to get for some people.

Despite the COVID-19 pandemic's hurdles, the global DES market is likely to rise in the future years. This is because cardiovascular disorders such as coronary artery disease and peripheral artery disease are becoming more common. These diseases are the top causes of mortality and disability around the world.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict is having a negative influence on the global market for drug eluting stents (DES). The war has caused interruptions in the worldwide supply chain, resulting in higher DES prices. Furthermore, the war has created economic instability, which has reduced demand for DES. As a result, the global DES market is likely to expand at a slower rate than it did prior to the war. 

The war has caused interruptions in the global supply chain, resulting in higher DES prices. This is due to the fact that DES are built from a range of components, some of which come from Russia or Ukraine. Palladium, for example, is a critical component in the production of DES, and Russia is a large producer of palladium. As a result of the battle, the price of palladium has risen, resulting in higher DES prices.

Because of the war's economic instability, demand for DES has fallen. This is because when there is economic uncertainty, people are less willing to spend money on elective operations such as coronary artery stenting. Thus, the global drug-eluting stent market is expected to expand at a slower rate than it did prior to the war. The market is still likely to develop, but at a slower rate than it would have been without the war.

Key Developments

• In May 2023, CoSo Health announced an agreement to distribute Medinol in the United States for EluNIR, a new generation, a thin-strut drug-eluting stent (DES). Medinol is a global innovator of revolutionary implantable medical devices. U.S. Endovascular sells peripheral and coronary devices throughout the United States.
• In April 2022, Translumina, a global developer and manufacturer of breakthrough cardiovascular medical devices used in interventional cardiology, announced the introduction of VIVO ISAR, its next-generation dual drug polymer-free coated stent (DDCS), in a number of foreign countries, including Europe.
• In May 2022, Medtronic plc, a global leader in healthcare technology, announced that the Onyx Frontier drug-eluting stent (DES) was approved by the United States Food and Drug Administration (FDA).

Why Purchase the Report?

• To visualize the global drug eluting stents market segmentation based on the coating, application, end user and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of drug eluting stents market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global drug eluting stents market report would provide approximately 49 tables, 53 figures, and 195 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies